101,089 AbbVie Inc. $ABBV Shares Sold by Miller Howard Investments Inc. NY

Miller Howard Investments Inc. NY reduced its holdings in AbbVie Inc. (NYSE:ABBV) by 25.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 295,568 shares of the company’s stock after selling 101,089 shares during the quarter. AbbVie comprises 2.1% of Miller Howard Investments Inc. NY’s investment portfolio, making the stock its 6th biggest holding. Miller Howard Investments Inc. NY’s holdings in AbbVie were worth $77,318,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Corient Private Wealth LP purchased a new position in AbbVie in the second quarter worth $559,736,000. Legal & General Group Plc acquired a new stake in AbbVie in the second quarter valued at $2,905,952,000. Jupiter Topco LLC acquired a new stake in AbbVie in the second quarter valued at $1,560,354,000. Diamant Asset Management Inc. boosted its position in shares of AbbVie by 21,649.0% during the 1st quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock worth $798,456,000 after purchasing an additional 3,654,351 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of AbbVie during the 2nd quarter worth $817,473,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Price Performance

NYSE ABBV opened at $286.88 on Tuesday. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $291.40. The company has a market capitalization of $506.85 billion, a P/E ratio of 81.04, a PEG ratio of 1.30 and a beta of 0.24. The business has a 50 day moving average price of $266.18 and a 200 day moving average price of $235.62.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. AbbVie’s revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts expect that AbbVie Inc. will post 13.93 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved a subcutaneous induction regimen for AbbVie’s SKYRIZI in adults with moderately to severely active Crohn’s disease. The needle-based treatment option may improve convenience and support the drug’s continued growth across immunology indications. FDA approves subcutaneous SKYRIZI regimen
• Positive Sentiment: Goldman Sachs raised its price target for ABBV to $294, signaling continued confidence in the company’s outlook and providing a bullish valuation reference. Goldman Sachs raises AbbVie price target
• Positive Sentiment: Reports that Citadel has built an approximately $900 million position in AbbVie may boost sentiment by highlighting institutional interest in the company’s dividend and growth profile. Citadel AbbVie position
• Neutral Sentiment: Options markets imply roughly a 5% move around the October 30 earnings release, indicating that investors expect significant volatility as they assess results and forward guidance. AbbVie options and earnings volatility
• Neutral Sentiment: Coverage continues to describe AbbVie as an attractive, income-focused “Dividend King,” although its high earnings multiple makes future performance dependent on sustained earnings growth. AbbVie Dividend King coverage
• Negative Sentiment: Erste Group Bank reduced its EPS forecast and expressed a weak outlook for AbbVie’s fiscal 2026 earnings, creating a counterweight to the favorable product and institutional news. Erste Group lowers AbbVie EPS forecast

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

Analyst Ratings Changes

ABBV has been the topic of a number of recent analyst reports. BNP Paribas Exane upped their price target on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Wells Fargo & Company increased their price target on shares of AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a report on Monday, August 17th. Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and raised their price objective for the company from $235.00 to $300.00 in a research note on Thursday, August 13th. JPMorgan Chase & Co. boosted their price objective on shares of AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a report on Thursday, October 8th. Finally, Piper Sandler upped their target price on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and an average target price of $279.86.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.